927880-90-8 | RAF265

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$31.00	$22.00
5mg	99%	in stock	$77.00	$54.00
10mg	99%	in stock	$113.00	$79.00
25mg	99%	in stock	$197.00	$138.00
50mg	99%	in stock	$320.00	$224.00

Description

• Catalog Number: AH85394
• Chemical Name: RAF265
• CAS Number: 927880-90-8
• Molecular Formula: C24H16F6N6O
• Molecular Weight: 518.4138591999999
• MDL Number: MFCD16659061
• SMILES: Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2c1ccc(c2)Oc1ccnc(c1)c1ncc([nH]1)C(F)(F)F

Computed Properties

• Complexity: 763
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 37
• Hydrogen Bond Acceptor Count: 11
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5
• XLogP3: 5.4

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111015

• Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors.

  International journal of oncology 20110901

• Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

  European journal of medicinal chemistry 20110601

• Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.

  Bioorganic & medicinal chemistry 20110601

• The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells.

  Endocrine-related cancer 20110401

• Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.

  Neoplasia (New York, N.Y.) 20110301

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination.

  Molecular cancer therapeutics 20100201

• A quantitative analysis of kinase inhibitor selectivity.

  Nature biotechnology 20080101